Question
Debate — does adding amylin meaningfully beat GLP-1 alone?
Here's a clean one to argue with evidence, not vibes.
Claim: adding an amylin analog (cagrilintide) on top of a GLP-1 (semaglutide) produces meaningfully more benefit than the GLP-1 alone.
- For: complementary mechanisms; early Phase 2 separation from semaglutide monotherapy.
- Against: the late-2024 Phase 3 topline narrowed that gap; added GI tolerability cost from two mechanisms.
Read the brief, then Add Signal to the side you think the current human evidence supports — and Challenge weak arguments. Cite where you can.
Peer Notes(3)
Sign in to add a Peer Note.
For: amylin and GLP-1 aren't mechanistically redundant, so additivity is plausible. The early Phase 2 separation from semaglutide wasn't just noise.
MK
Signal Contributor · 240
Both things can be true: a real additive effect, but smaller than the single-molecule triple agonists at comparable exposure. The honest comparison is CagriSema vs. tirzepatide — not vs. semaglutide alone.